CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Anthera Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Anthera Pharmaceuticals Inc
25801 INDUSTRIAL BOULEVARD, SUITE B
Phone: (510) 856-5600p:510 856-5600 HAYWARD, CA  94545  United States Ticker: ANTHANTH
This company ceased filing statements with the SEC on 7/30/2018.
Business Summary
Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/201812/31/2017YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board Paul F.Truex 12/6/2016 9/1/2004
President, Chief Executive Officer, Director J. CraigThompson 51 12/6/2016 1/7/2016
Senior Vice President - Finance and Administration, Principal Accounting Officer MayLiu 42 6/12/2013 6/12/2013
5 additional Officers and Directors records available in full report.

Business Names
Business Name
ANTH
Anthera Pharmaceuticals
Anthera Pharmaceuticals Inc
4 additional Business Names available in full report.

General Information
Number of Employees: 21 (As of 12/31/2017)
Outstanding Shares: 26,179,302 (As of 6/28/2018)
Shareholders: 55
Stock Exchange: OTC
Federal Tax Id: 201852016
Fax Number: (510) 856-5597


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, December 30, 2023